Dry powder inhaler and methods of use
AssigneeOtitopic Inc.
InventorKambiz YADIDI
Life of this patent
Estimating the term…
Abstract
Methods for reducing the risk of a thromboembolic event, and a related drug delivery system are provided. In some embodiments, a dose of acetylsalicylic acid can be provided in powder form to a patient using a dry powder inhaler. The dose can be effective to reduce a risk of a thromboembolic event in a patient. A dry powder inhaler used for the method can have a mouthpiece, a reservoir for receiving the dose of acetylsalicylic acid, and an actuation member for making available the dose of acetylsalicylic acid for inhalation by a patient through the mouthpiece.
Claims19
A method of reducing the risk of a thromboembolic event, comprising administering a dose of acetylsalicylic acid, the dose effective to reduce a risk of a thromboembolic event in a patient, by a dry powder inhaler, the dry powder inhaler having a mouthpiece and an actuation member for making available the dose of the acetylsalicylic acid for inhalation by the patient to reduce the risk of the thromboembolic event, wherein the amount of the dose administered comprises less than about 80 mg of the acetylsalicylic acid.
A drug delivery system for reducing the risk of a thromboembolic event, the system comprising:
- a dose of acetylsalicylic acid in powder form, the dose effective to reduce a risk of a thromboembolic event in a patient;
- a dry powder inhaler, the dry powder inhaler having a mouthpiece, a reservoir for receiving the dose of the acetylsalicylic acid, and an actuation member for making available the dose of the acetylsalicylic acid for inhalation by the patient through the mouthpiece,
- wherein the amount of the dose of the acetylsalicylic acid comprises less than about 80 mg of the acetylsalicylic acid.
Dependencies are inferred from the claim text.